KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Emergent BioSolutions (EBS) Invested Capital (2016 - 2025)

Emergent BioSolutions (EBS) has 16 years of Invested Capital data on record, last reported at $589.7 million in Q4 2025.

  • For Q4 2025, Invested Capital fell 50.14% year-over-year to $589.7 million; the TTM value through Dec 2025 reached $589.7 million, down 50.14%, while the annual FY2025 figure was $589.7 million, 50.14% down from the prior year.
  • Invested Capital reached $589.7 million in Q4 2025 per EBS's latest filing, down from $1.3 billion in the prior quarter.
  • Across five years, Invested Capital topped out at $2.8 billion in Q4 2022 and bottomed at $589.7 million in Q4 2025.
  • Average Invested Capital over 5 years is $1.9 billion, with a median of $1.9 billion recorded in 2023.
  • Peak YoY movement for Invested Capital: rose 27.61% in 2021, then tumbled 50.14% in 2025.
  • A 5-year view of Invested Capital shows it stood at $2.5 billion in 2021, then increased by 13.83% to $2.8 billion in 2022, then crashed by 45.83% to $1.5 billion in 2023, then dropped by 22.07% to $1.2 billion in 2024, then plummeted by 50.14% to $589.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Invested Capital were $589.7 million in Q4 2025, $1.3 billion in Q3 2025, and $1.2 billion in Q2 2025.